Thromb Haemost 2006; 95(04): 749-750
DOI: 10.1160/TH05-11-0774
Letters to the Editor
Schattauer GmbH

Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus

Fang Liu
1   Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
,
Hendrik B. Feys
2   Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium
,
NingZheng Dong
1   Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
,
Yiming Zhao
1   Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
,
Changgeng Ruan
1   Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
› Institutsangaben
Financial support: HBF is granted with a spezialisation scholarship from the ‘Instituut voor de aanmoediging van Innovatie door Wetenschap en TEchnologie in Vlaanderen’ IWT-21394.
Weitere Informationen

Publikationsverlauf

Received 29. November 2005

Accepted after revision 10. Februar 2006

Publikationsdatum:
30. November 2017 (online)

 

 
  • References

  • 1 Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
  • 2 Furlan M, Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 1998; 11: 509-14.
  • 3 Sadler JE, Moake JL, Miyata T. et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology 2004; 407-23.
  • 4 Moore CJ, Hayward PMC, Warkentin ET. et al. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-6.
  • 5 Rick ME, Moll S, Taylor MA. et al. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2002; 88: 598-604.
  • 6 Xi XD, Ruan CG, Li PX. et al. Evaluation of vWF in diseases by a newly developed ELISA basing on anti-vWF monoclonal antibody. Chin J Lab Med 1988; 12: 272-5.
  • 7 Rieger M, Ferrari S, Herzog A. et al. Quantification of ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies by a newly developed sandwich ELISA. Blood (ASH Annual Meeting Abstracts) 2004; 104: 3944.
  • 8 Feys HB, Liu F, Dong N. et al. Newly developed ADAMTS13 antigen assay reveals marked ethnic differences and depletion in acquired thrombotic thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts) 2005; 106: 1251.
  • 9 Studt JD, Hovinga JA, Radonic R. et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood 2004; 103: 4195-7.